Asia
PeptiDream Partner Begins Phase 1 Trial of TNFR1 Inhibitor AK1940
PeptiDream (TYO:4587) said its partner Asahi Kasei Therapeutics has started a Phase 1 clinical trial of AK1940, a TNFR1 inhibitor discovered using its peptide platform, according to a Monday filing on the Tokyo Stock Exchange.The candidate targets autoimmune diseases and showed efficacy in preclinical studies, the company said.PeptiDream will receive a milestone payment and is eligible for further payments and royalties tied to development and sales.
TYO:4587
